---
canonical_name: Topical Urolithin A
alternate_names: "Urolithin A, UA, Mitopure, 3,8-dihydroxy-6H-dibenzo[b,d]pyran-6-one"
canonical_topic: Topical Urolithin A for Skin Rejuvenation
short_topic_lc: topical_urolithin_a_skin
creation_date: 2026-1024-0802
creator_ai_fullname: Opus 5.5
ep_keywords: Urolithins, Ellagitannin Metabolites, Postbiotics
---

# Topical Urolithin A for Skin Rejuvenation
<section id="top" markdown="1"></section>  
Evidence Review created on 10/24/2026 using [AI4L](https://github.com/forever-healthy/AI4L) / Opus 5.5

**Also known as:** Urolithin A, UA, Mitopure, 3,8-dihydroxy-6H-dibenzo[b,d]pyran-6-one

  
## Motivation

<!-- Author statement: This Motivation section was written only after all other sections of the document were completed, so that it reflects the full scope of the topic. -->

Urolithin A is a compound that gut bacteria make from plant substances in pomegranates, berries and walnuts. Taken by mouth, it has been studied for helping cells clear out and replace worn-out mitochondria, the tiny structures that supply cells with energy. Skin cells also depend on healthy mitochondria, and their decline is thought to contribute to wrinkles, thinning and slower repair. This idea has led to creams and serums that apply purified urolithin A directly to the skin.

Interest grew after the company that developed purified urolithin A ran trials of face and arm creams in middle-aged adults, measuring wrinkles, redness after sun exposure and gene activity in small skin samples. A major cosmetics group has since invested in that company and launched a luxury skincare range built on the ingredient, bringing it to a much wider market.

This review examines urolithin A applied to the skin for adults who want to keep their skin healthy as they age: how it is thought to work, how strong and independent the human evidence is, possible harms, how it was used in trials, and what remains unknown.

**[Benefits](#expected-benefits) - [Risks](#potential-risks--side-effects) - [Protocol](#therapeutic-protocol) - [Conclusion](#conclusion)**

  
## Recommended Reading

Expert commentary and research that give an overview of topical urolithin A and the mitochondrial biology behind it.

<!-- Search statement: On 2026-10-23 the author ran real-time web searches (WebSearch) for "urolithin A" with "topical", "skin", "cream" and each priority expert's name, plus on-site searches via d-browser: foundmyfitness.com (several urolithin A clips, oral focus), peterattiamd.com/?s=urolithin (results page "Nothing Found", but the site's search dialog returned episode #357 with Brian Kennedy, whose urolithin A segment runs about 3.5 minutes, too brief to list), hubermanlab.com search ("No results found", but the site search returns no results for any term; web search found the Dr. Chris Palmer episode, which reviews urolithin A as an oral supplement), chriskresser.com/?s=urolithin (one gut-health episode with a brief urolithin mention), lifespan.io (several urolithin A articles, none on skin), lifeextension.com (2017 magazine article on urolithin A and mitochondria; d-browser returned "Access Denied", d-fetch loaded it). PubMed and Europe PMC were searched for narrative reviews and primary research on urolithin A and skin. ai.hubermanlab.com was excluded as AI-generated content. -->

- [Topical application of urolithin A activates mitophagy and enhances mitochondrial function to promote skin longevity.](https://pubmed.ncbi.nlm.nih.gov/42866687/) - D'Amico et al., 2026

  The only peer-reviewed controlled human evidence for topical urolithin A on skin aging: skin-model data plus wrinkle, sunburn and patch-test trials, sponsored by Amazentis (Timeline), with L'Oréal co-authors.

- [Role of Mitochondrial Dynamics in Skin Homeostasis: An Update.](https://pubmed.ncbi.nlm.nih.gov/40076431/) - Quan et al., 2025

  Reviews mitochondrial quality control in skin cells, including mitophagy (the clearance of damaged mitochondria), the mechanism topical urolithin A targets, and how mitochondrial dysfunction contributes to skin aging.

- [How Urolithin A Supports Mitochondrial Health](https://www.foundmyfitness.com/episodes/how-urolithin-a-supports-mitochondrial-health) - Rhonda Patrick

  Explains mitophagy, the mechanism topical products rely on, and weighs the oral trial results critically, including null primary outcomes; it does not address skin application.

- [A Gut Metabolite Reduces Senescence and Inflammation](https://lifespan.io/a-gut-metabolite-reduces-senescence-and-inflammation/) - Arkadi Mazin

  Covers evidence that urolithin A acts as a senomorphic (dampening inflammatory secretions of senescent, permanently non-dividing cells), the activity claimed in skin biopsies; the cells studied were lung fibroblasts (connective-tissue cells).

- [Pomegranate Improves Markers of Aging](https://www.lifeextension.com/magazine/2017/9/pomegranate-improves-markers-of-aging) - Alma Ross

  Summarizes the foundational worm and rodent research showing urolithin A triggers mitophagy and extends worm lifespan, the work that later prompted skin applications.

Peter Attia's episode #357 with Brian Kennedy covers oral urolithin A in a segment of about 3.5 minutes within a broad longevity discussion, too brief to list. Andrew Huberman's episode with Dr. Chris Palmer has a short segment on urolithin A as an oral mitochondrial supplement; it was not listed because it overlaps the FoundMyFitness item and the five-item limit was reached. Chris Kresser mentions urolithin A only briefly as a gut metabolite in a gut-health episode and a phytochemicals article, so no Kresser item was listed.

  
## Grokipedia

<!-- Search statement: On 2026-10-23 grokipedia.com/search?q=urolithin+A was loaded with d-browser (first tier), which returned the search results page listing a dedicated "Urolithin A" article (/page/Urolithin_A); the article page then loaded with d-browser. Lower tiers were not needed. -->

[Urolithin A](https://grokipedia.com/page/Urolithin_A)

A general article on chemistry, mitophagy research, oral trials and safety; skin use appears only as a brief mention of the manufacturer's skincare line, without evaluating topical evidence.

  
## Examine

<!-- Search statement: On 2026-10-23 examine.com/search/?q=urolithin was tried with d-browser (returned a "Vercel Security Checkpoint" bot wall), then d-fetch (HTTP 429 error), then d-proxy-1, which returned the search results listing the dedicated "Urolithin A" supplement page; d-proxy-1 then loaded examine.com/supplements/urolithin-a/. -->

[Urolithin A](https://examine.com/supplements/urolithin-a/)

Covers oral urolithin A, mainly muscle function and endurance trials, with an independent evidence summary; it does not evaluate topical or skin applications.

  
## ConsumerLab

<!-- Search statement: On 2026-10-23 consumerlab.com/search/?q=urolithin was loaded with d-browser (first tier), which returned a CL Answer on urolithin A; the article page then loaded with d-browser. Lower tiers were not needed. -->

[Does urolithin A reduce age-related muscle decline, osteoarthritis, or other age-related diseases?](https://www.consumerlab.com/answers/does-urolithin-a-reduce-age-related-muscle-decline/urolithin-a-for-muscle-health/)

Reviews evidence, safety and product quality for oral urolithin A supplements, including Timeline Mitopure; it does not address skin creams or topical use.

  
## Systematic Reviews

Systematic reviews of urolithin A exist only for oral use; none covers topical application or skin outcomes.

<!-- Search statement: On 2026-10-23 PubMed was searched for "urolithin AND (systematic review OR meta-analysis)" (14 hits) and Europe PMC for urolithin A with topical, cream, cosmetic or skin terms. No systematic review or meta-analysis of topical urolithin A or of urolithin A for any skin outcome exists. The listed review was chosen for direct relevance to the compound's human safety; a meta-analysis of oral urolithin A on muscle outcomes (Dao et al., 2026) was not listed because it does not bear on topical use or skin; a review of pomegranate dermocosmetics (Pons-Rocamora et al., 2026) does not cover urolithin A. -->

- [Targeting aging with urolithin A in humans: A systematic review.](https://pubmed.ncbi.nlm.nih.gov/39002645/) - Kuerec et al., 2024

  Five oral trials (250 adults): dose-dependent anti-inflammatory signals and only mild-to-moderate unrelated adverse events; informs systemic safety, not skin effects.

No systematic review addresses the claimed skin benefit; the principal risk is represented only by oral safety data.

  
## Mechanism of Action

Urolithin A is a small, fat-soluble polyphenol (plant-derived compound with ring-shaped phenol groups) metabolite. Its proposed skin effects rest on four mechanisms, shown mainly in cell and tissue models ([D'Amico et al., 2026](https://pubmed.ncbi.nlm.nih.gov/42866687/)):

- **Mitophagy:** urolithin A activates the PINK1–Parkin pathway (two enzymes that tag damaged mitochondria for recycling), so cells replace faulty mitochondria; in skin models this raised oxygen use and mitochondrial content.
- **Antioxidant signaling:** in fibroblasts exposed to UVA (long-wave ultraviolet light), it activated Nrf2 (a master switch for antioxidant enzymes) ([Liu et al., 2022](https://pubmed.ncbi.nlm.nih.gov/35567884/)).
- **Matrix preservation:** it lowered MMP-1 (matrix metalloproteinase 1, an enzyme that breaks down collagen) and raised type I collagen in aged fibroblasts ([Liu et al., 2019](https://pubmed.ncbi.nlm.nih.gov/30215291/)).
- **Inflammation and senescence:** it reduced IL-6 (interleukin 6, an inflammatory messenger) and SASP genes (senescence-associated secretory phenotype, the inflammatory output of senescent cells), and blocks AhR (aryl hydrocarbon receptor, a pollutant-sensing protein) ([Muku et al., 2018](https://pubmed.ncbi.nlm.nih.gov/30501068/)).

The competing reading: no study has measured urolithin A inside skin after application, so clinical effects could partly reflect the cream base; high concentrations also halt fibroblast division.

**Pharmacology:** skin half-life, tissue levels and metabolism after topical use are unmeasured. Taken orally, it is conjugated by UGT enzymes (UDP-glucuronosyltransferases, liver and gut enzymes that attach glucuronic acid for excretion) and by sulfation, peaks at about 6 hours and has a circulating half-life of about one day ([Singh et al., 2022](https://pubmed.ncbi.nlm.nih.gov/34117375/), a study by the manufacturer, Amazentis). It is not selective for a single receptor.

  
## Historical Context & Evolution

Urolithins were identified decades ago as compounds that gut bacteria produce from ellagitannins (tannins in pomegranates, berries and nuts); they had no original medical use and were studied mainly to explain pomegranate's health effects ([D'Amico et al., 2021](https://pubmed.ncbi.nlm.nih.gov/34030963/), a sponsor-authored review).

Health-optimization interest began in 2016, when researchers linked to the Swiss company Amazentis reported that urolithin A triggers mitophagy, extends worm lifespan and improves rodent muscle function ([Ryu et al., 2016](https://pubmed.ncbi.nlm.nih.gov/27400265/)). Genotoxicity (DNA damage) assays and rat toxicology studies co-authored by Amazentis found no genotoxicity or target-organ toxicity ([Heilman et al., 2017](https://pubmed.ncbi.nlm.nih.gov/28757461/)), the FDA (U.S. Food and Drug Administration) closed a GRAS (generally recognized as safe) notice for food use with no questions in 2018 ([GRN 791](https://www.hfpappexternal.fda.gov/scripts/fdcc/index.cfm?set=GRASNotices&id=791)), and a first Amazentis-run human trial found oral doses well tolerated ([Andreux et al., 2019](https://pubmed.ncbi.nlm.nih.gov/32694802/)).

Skin interest grew from independent cell studies showing collagen preservation ([Liu et al., 2019](https://pubmed.ncbi.nlm.nih.gov/30215291/)) and ultraviolet protection ([Liu et al., 2022](https://pubmed.ncbi.nlm.nih.gov/35567884/)) in fibroblasts. The sponsor ran a patch test and three efficacy trials in 2021–2022, posted the efficacy trials as a 2023 preprint ([D'Amico et al., 2023](https://www.medrxiv.org/content/10.1101/2023.06.16.23291378v1)), and L'Oréal invested in the company in 2024; Lancôme launched a urolithin A range in 2026 ([NutraIngredients](https://www.nutraingredients.com/Article/2026/02/13/lancome-launches-topical-longevity-skincare-with-timeline/)).

What changed by 2026: pooled oral muscle results proved inconclusive ([Dao et al., 2026](https://pubmed.ncbi.nlm.nih.gov/42559151/)), and the peer-reviewed topical report ([D'Amico et al., 2026](https://pubmed.ncbi.nlm.nih.gov/42866687/)) included two of the three preprint trials but omitted the largest. No independent group has tested topical urolithin A on skin aging, so the picture remains provisional.

  
## Expected Benefits

<!-- Search statement: Before writing this section, on 2026-10-23 the author searched PubMed ("urolithin A skin"; urolithin with skin, dermal, wrinkle, photoaging, keratinocyte, collagen, dermatitis, psoriasis, melanoma; "urolithin A randomized placebo-controlled"), Europe PMC (urolithin A with topical, cream, serum, cosmetic, skin aging, wrinkle; this found the 2023 medRxiv preprint), ClinicalTrials.gov (urolithin or Mitopure with skin, topical, cream, wrinkle, hair; all Amazentis-sponsored studies), and web sources (FoundMyFitness, Lifespan.io, Examine, ConsumerLab, Grokipedia, trade press). The search also looked for studies of any design that found no effect or the opposite effect: the 0.5% concentration showed no effect on wrinkles or redness, and the placebo-controlled trial found no change in skin barrier function; no independent trial was found. -->

### High 🟩 🟩 🟩

No benefit reaches High: every controlled human trial of topical urolithin A comes from a single sponsor-led research group (Amazentis with L'Oréal), and none has been replicated independently.

### Medium 🟩 🟩

#### Reduced Wrinkle Depth Around the Eyes

In a randomized split-face trial (active cream on one side, placebo on the other) of 48 women averaging 59 years, 1% urolithin A cream twice daily for 8 weeks reduced crow's-feet wrinkle depth versus placebo; 0.5% had no effect ([D'Amico et al., 2026](https://pubmed.ncbi.nlm.nih.gov/42866687/)). Wrinkles were secondary; registered primary outcomes were biopsy markers and barrier function ([NCT05300984](https://clinicaltrials.gov/study/NCT05300984)). Most authors were employees of sponsor Amazentis or its partner L'Oréal, and Amazentis holds related patents. An open-label trial (participants knew their product) also reported wrinkle reductions versus untreated skin ([D'Amico et al., 2023](https://www.medrxiv.org/content/10.1101/2023.06.16.23291378v1)).

**Magnitude:** Mean wrinkle depth changed by −3.4% from baseline on the 1% urolithin A side versus +4.0% on the placebo side at 8 weeks (22 participants; p = 0.04, p being the probability of a difference this large arising by chance); the paper gives no between-side difference figure or 95% confidence interval (the range likely to contain the true effect).

#### Reduced Redness After Ultraviolet Exposure

In a randomized trial of 21 healthy adults, 1% urolithin A cream applied around UVB (short-wave, sunburn-causing ultraviolet) exposure reduced erythema (skin redness) versus untreated skin, while 0.5% urolithin A and the placebo cream showed no significant benefit versus untreated skin ([D'Amico et al., 2026](https://pubmed.ncbi.nlm.nih.gov/42866687/)). The abstract calls the trial placebo-controlled, but the full text compares each cream only with untreated skin, never 1% urolithin A directly with placebo. The trial was sponsor-run and has not been replicated.

**Magnitude:** 13% less redness than the untreated site after 1.6 times the minimal sunburn dose (p = 0.02); the placebo cream did not differ significantly from untreated skin, but no direct comparison of 1% urolithin A with placebo is reported.

### Low 🟩

#### Improved Skin Hydration

The open-label trial of 1% urolithin A day cream, night cream and serum in 108 middle-aged adults reported improved hydration versus untreated skin ([D'Amico et al., 2023](https://www.medrxiv.org/content/10.1101/2023.06.16.23291378v1)). The peer-reviewed report omits this trial ([D'Amico et al., 2026](https://pubmed.ncbi.nlm.nih.gov/42866687/)); the preprint also reports no barrier-function change in the placebo-controlled trial.

**Magnitude:** Direction only: hydration was reported as significantly higher than on untreated skin after 8 weeks; the preprint text gives no outcome figure, showing values only in its graphs and a supplementary table.

#### Thicker Hair Roots and Less Shedding ⭕️ Not Central to Skin Rejuvenation

Authors from Paean Biotechnology reported that topical urolithin A increased hair root volume and reduced shedding in clinical cases, alongside protection of hair-follicle cells from oxidative stress ([Kwon et al., 2026](https://pubmed.ncbi.nlm.nih.gov/42337978/)). This bears on scalp hair, not skin aging; design and controls are not described.

**Magnitude:** Not quantified in available studies. The abstract reports direction only and gives no participant numbers, figures or comparison group.

### Speculative 🟨

#### Increased Collagen and Elastic-Fiber Production

In aged-donor three-dimensional skin models, urolithin A raised collagen III, collagen VII, elastin and hyaluronic acid; forearm biopsies showed collagen-gene upregulation ([D'Amico et al., 2026](https://pubmed.ncbi.nlm.nih.gov/42866687/)). Gene expression is unvalidated; basis is mechanistic.

#### Dampened Skin Inflammation and Senescence Signals

Urolithin A lowered IL-6, p16 (a senescent-cell marker) and inflammatory and SenMayo (a published senescence gene panel) gene sets in skin models and biopsies ([D'Amico et al., 2026](https://pubmed.ncbi.nlm.nih.gov/42866687/)). Basis is mechanistic only.

#### Protection Against UVA and Pollution Damage

In fibroblasts and skin explants (donated skin kept alive in the laboratory), urolithin A limited UVA-induced senescence and pollution-plus-UVA protein oxidation ([Liu et al., 2022](https://pubmed.ncbi.nlm.nih.gov/35567884/); [D'Amico et al., 2026](https://pubmed.ncbi.nlm.nih.gov/42866687/)). No human outcome data exist.

#### Lighter Pigmentation

Urolithin A inhibited tyrosinase (the melanin-producing enzyme) and reduced melanin in mouse melanoma (skin cancer) cells comparably to kojic acid, a skin-lightening agent ([Wang et al., 2017](https://pubmed.ncbi.nlm.nih.gov/28726389/)). Basis is cell data only.

#### Faster Wound Repair ⭕️ Not Central to Skin Rejuvenation

In rats given oral urolithin A, full-thickness wounds formed more new blood vessels and remodeled collagen faster ([Feng et al., 2022](https://pubmed.ncbi.nlm.nih.gov/35359856/)). This bears on wound healing, not skin aging, and used another route.

  
## Benefit-Modifying Factors

- **Genetic polymorphisms:** No study has examined genetic variants. Gut "producer" status governs exposure from dietary precursors, not from direct supplements ([Singh et al., 2022](https://pubmed.ncbi.nlm.nih.gov/34117375/)), and is not expected to matter for cream applied directly; whether natural producers already have higher skin levels is unknown.
- **Baseline wrinkle severity:** The open-label trial enrolled adults with visible wrinkles graded 3 to 6 on a dermatology scale ([NCT05473832](https://clinicaltrials.gov/study/NCT05473832)); effects on smooth or severely sun-damaged skin are untested. No blood or skin biomarker is known to predict response.
- **Sex:** The placebo-controlled wrinkle trial enrolled only women; the sunburn trial included 10 men and 11 women without a sex-specific analysis ([D'Amico et al., 2026](https://pubmed.ncbi.nlm.nih.gov/42866687/)), so sex differences in benefit are unknown.
- **Pre-existing conditions:** People with active skin disease, diabetes or recent cosmetic procedures were excluded ([NCT05473832](https://clinicaltrials.gov/study/NCT05473832)); benefits in rosacea (chronic facial redness), eczema (itchy, inflamed skin) or diabetic skin are unknown.
- **Age:** The wrinkle trial enrolled women aged 50 to 75 ([NCT05300984](https://clinicaltrials.gov/study/NCT05300984)) with a mean age of 58.6 years and no age-specific analysis ([D'Amico et al., 2026](https://pubmed.ncbi.nlm.nih.gov/42866687/)); benefit in adults past 75 is unstudied.
- **Skin type and ethnicity:** All participants in the published trials were Caucasian ([D'Amico et al., 2026](https://pubmed.ncbi.nlm.nih.gov/42866687/)); response in darker skin types is unknown.

  
## Potential Risks & Side Effects

<!-- Search statement: Before writing this section, on 2026-10-23 the author searched drug reference sources: drugs.com (d-browser "Access Denied"; d-fetch returned search results with no urolithin A monograph, only a LactMed pomegranate breastfeeding entry), plus PubMed (urolithin with safety, sensitization, contact dermatitis, phototoxicity, platelet, drug interaction, pharmacokinetics), ClinicalTrials.gov (Amazentis topical safety studies NCT05079607, NCT06884215, NCT07100912, NCT07517874, NCT07517900; no results posted), and the oral safety literature (Heilman 2017, Andreux 2019, Kuerec 2024). No product label or regulator safety document exists for topical urolithin A. The search also covered studies finding no excess risk: the patch test and 8-week trial reported no reactions. -->

### High 🟥 🟥 🟥

No risk reaches High: human safety data for topical urolithin A consist of sponsor-run patch tests and short trials from a single research group.

### Medium 🟥 🟥

No risk reaches Medium: the only documented adverse events, mild irritation in a few trial participants, come without comparison-group rates, so they remain uncontrolled human data.

### Low 🟥

#### Skin Irritation or Allergic Contact Reaction ⚠️ Conflicted

Any cosmetic active can irritate or sensitize. An HRIPT (human repeat insult patch test, repeated covered patches) and the placebo-controlled trial found no reactions ([D'Amico et al., 2026](https://pubmed.ncbi.nlm.nih.gov/42866687/)); the open-label trial reported mild irritation ([D'Amico et al., 2023](https://www.medrxiv.org/content/10.1101/2023.06.16.23291378v1)). Net: rare, mild irritation without excess over placebo in sponsor-run controlled data.

**Magnitude:** No reactions in the 112-person patch test ([NCT05079607](https://clinicaltrials.gov/study/NCT05079607); no control group) or on either side of the 48-person placebo-controlled trial; the open-label trial reported 4 mild irritation reactions (redness, papules or small raised bumps, itching, burning) in 3 of 108 participants and the sunburn trial 2 in 1 participant, with no comparison-group rates.

### Speculative 🟨

#### Growth Arrest of Skin Cells at High Concentrations

At 50 µM (micromolar), urolithin A halted fibroblast division and altered cell shape without causing senescence or cell death ([Liu et al., 2019](https://pubmed.ncbi.nlm.nih.gov/30215291/)). Skin concentrations after cream use are unknown; basis is mechanistic.

#### Disturbed Skin Barrier Signaling ⚠️ Conflicted

Urolithin A blocks AhR ([Muku et al., 2018](https://pubmed.ncbi.nlm.nih.gov/30501068/)), whose activation upregulates filaggrin and other barrier proteins ([Furue et al., 2015](https://pubmed.ncbi.nlm.nih.gov/26276439/)). Yet skin models showed increased filaggrin. Net: a mechanistic concern without supporting data.

#### Increased Bleeding Tendency if Absorbed

Urolithin A inhibited human platelet aggregation in laboratory tests and strengthened aspirin's effect ([Soloviova et al., 2026](https://pubmed.ncbi.nlm.nih.gov/42812264/)). Absorption from skin has never been measured; basis is laboratory only.

  
## Risk-Modifying Factors

- **Genetic polymorphisms:** No genetic variant has been studied. Orally absorbed urolithin A is cleared mainly as glucuronide conjugates ([Singh et al., 2022](https://pubmed.ncbi.nlm.nih.gov/34117375/)); whether variants in conjugating enzymes matter after skin application is unknown.
- **Baseline biomarkers:** No laboratory marker predicts risk. People with documented allergies to face or eye care products were excluded from trials ([NCT05473832](https://clinicaltrials.gov/study/NCT05473832)), so a history of cosmetic contact allergy is the most relevant baseline factor.
- **Sex:** No sex difference in tolerability has been reported; the sunburn trial included both sexes, while the wrinkle trial enrolled only women ([D'Amico et al., 2026](https://pubmed.ncbi.nlm.nih.gov/42866687/)).
- **Pre-existing conditions:** Eczema, rosacea and broken or recently treated skin raise irritation risk with any cosmetic and were excluded from trials ([NCT05473832](https://clinicaltrials.gov/study/NCT05473832)); bleeding disorders warrant caution (theoretical) given laboratory antiplatelet data.
- **Age:** The placebo-controlled trial enrolled women up to 75 ([NCT05300984](https://clinicaltrials.gov/study/NCT05300984)) and the patch test had no upper age limit ([NCT05079607](https://clinicaltrials.gov/study/NCT05079607)), both without reactions, but no age-specific tolerability data exist for older, more fragile skin.
- **Pregnancy and lactation:** Pregnant and lactating women were excluded ([NCT05473832](https://clinicaltrials.gov/study/NCT05473832)), so safety during pregnancy and breastfeeding is unstudied.

  
## Key Interactions & Contraindications

<!-- Search statement: Before writing this section, on 2026-10-23 the author searched PubMed for urolithin with "drug interaction", pharmacokinetics, cytochrome, CYP, UGT and glucuronidation (154 hits, none a human interaction study), ClinicalTrials.gov for topical or combined oral-topical urolithin A studies, and drugs.com (no monograph). No human interaction or pharmacokinetic study of topical urolithin A exists; only a laboratory platelet study (Soloviova 2026) addresses a drug combination (aspirin). -->

No human interaction or pharmacokinetic (absorption and clearance) study of topical urolithin A exists; each interaction below is theoretical unless a study is cited.

- **Prescription topical retinoids (tretinoin, tazarotene; vitamin A–derived skin drugs):** Caution (theoretical): layering actives may add redness and peeling. Trials excluded vitamin A treatment within 2 weeks ([NCT05473832](https://clinicaltrials.gov/study/NCT05473832)). Mitigation: one product introduced at a time.
- **Anticoagulant and antiplatelet drugs (warfarin, apixaban, clopidogrel; drugs that slow blood clotting):** Monitor (theoretical): urolithin A inhibited platelets in laboratory tests ([Soloviova et al., 2026](https://pubmed.ncbi.nlm.nih.gov/42812264/)), but skin absorption is unmeasured, so added bleeding risk is unproven. Mitigation: monitoring for unusual bruising.
- **Over-the-counter aspirin and NSAIDs (nonsteroidal anti-inflammatory drugs: aspirin, ibuprofen, naproxen):** Monitor (theoretical): urolithin A strengthened aspirin's antiplatelet effect in laboratory tests ([Soloviova et al., 2026](https://pubmed.ncbi.nlm.nih.gov/42812264/)), so added bruising or bleeding is conceivable; relevance after skin application is unknown. Mitigation: noting unusual bruising.
- **Over-the-counter benzoyl peroxide and alpha-hydroxy acids (exfoliating fruit-derived acids: glycolic, lactic acid):** Caution (theoretical): oxidizing or acidic products may add irritation and could degrade a phenolic active. Mitigation: application at a different time of day.
- **Oral urolithin A supplements (Mitopure softgels, generic urolithin A capsules):** Monitor (theoretical): combined routes raise total exposure, with unknown local or systemic consequences; combined oral-plus-topical use was tested in a completed, unpublished trial ([NCT06932770](https://clinicaltrials.gov/study/NCT06932770)).
- **Supplements with additive antiplatelet activity (fish oil, ginkgo, high-dose vitamin E):** Monitor (theoretical): additive bruising is conceivable only if meaningful absorption occurs; no study exists. Mitigation: noting unusual bruising.
- **Other topical antioxidants (vitamin C serum, niacinamide):** No interaction expected (theoretical); possibly complementary against sun-induced skin aging, but no combined study exists.
- **Aesthetic procedures (laser, chemical peels, microneedling or fine-needle skin puncturing, IPL or intense pulsed light):** Caution (theoretical): barrier damage may raise absorption and irritation. Trials excluded peels, IPL and dermabrasion (mechanical resurfacing) within 2 years and any past laser ([NCT05473832](https://clinicaltrials.gov/study/NCT05473832)). Mitigation: pausing until healed.

**Populations who should avoid Topical Urolithin A:**

- Pregnant or breastfeeding women (excluded from trials; no safety data) ([NCT05473832](https://clinicaltrials.gov/study/NCT05473832))
- People with active skin disease, wounds or irritated skin at the application site ([NCT05473832](https://clinicaltrials.gov/study/NCT05473832))
- People with documented allergies to face or eye care products ([NCT05473832](https://clinicaltrials.gov/study/NCT05473832))
- People within 2 weeks of vitamin A or fruit-acid peel treatment, within 2 years of IPL, chemical peel, dermabrasion or botulinum toxin, or after any past laser treatment at the site (trial exclusion thresholds) ([NCT05473832](https://clinicaltrials.gov/study/NCT05473832))
- People with known allergy to urolithin A or any excipient (inactive ingredient) in the product

  
## Risk Mitigation Strategies

Doses and timings below follow common practice unless cited.

- **Forearm patch test before facial use:** the product is applied to the inner forearm twice daily for 7 days, and use stops if redness, itching, swelling or blistering appears. Mitigates irritation and allergic contact reaction before facial exposure.
- **One new active at a time:** urolithin A is used alone for 2 weeks before retinoids or acids are added. Mitigates cumulative irritation and makes the cause of any reaction identifiable.
- **Studied concentration and frequency only:** 1% twice daily, as in the controlled trial ([NCT05300984](https://clinicaltrials.gov/study/NCT05300984)), without layering several urolithin A products. Mitigates untested higher local concentrations linked to fibroblast growth arrest in cells.
- **Pause around procedures:** use stops 1 week before laser, peels or microneedling and resumes after full healing. Mitigates irritation and increased absorption through disrupted skin.
- **Bruising watch with anticoagulant or antiplatelet drugs:** new or unusual bruising is noted during the first 4 weeks of combined use. Mitigates the theoretical added bleeding risk.
- **Stop at persistent reaction:** use ends if redness or stinging lasts beyond 48 hours after an application. Mitigates progression of irritation or allergic contact reaction.
- **Deferral in pregnancy and lactation:** use is deferred until breastfeeding ends. Mitigates unstudied exposure of the fetus or infant.

  
## Therapeutic Protocol

Timing, amounts, titration and other parameters without a citation reflect common practice.

- **Concentration:** 1% urolithin A in a cream base; 0.5% showed no measurable effect on wrinkles or redness ([D'Amico et al., 2026](https://pubmed.ncbi.nlm.nih.gov/42866687/)).
- **Frequency and split dosing:** twice daily, morning and evening, on face and forearms in the controlled trial ([NCT05300984](https://clinicaltrials.gov/study/NCT05300984)); split into two applications rather than a single daily dose.
- **Time of day:** morning under sunscreen and evening after cleansing; the open-label trial used day cream mornings, night cream evenings and serum twice daily ([NCT05473832](https://clinicaltrials.gov/study/NCT05473832)). No data favor one time.
- **Duration:** at least 8 weeks of continuous use before judging effect, matching the trial duration ([D'Amico et al., 2026](https://pubmed.ncbi.nlm.nih.gov/42866687/)).
- **Half-life:** residence time in skin after application is unmeasured; oral urolithin A circulates with a half-life of about one day ([Singh et al., 2022](https://pubmed.ncbi.nlm.nih.gov/34117375/)). Twice-daily use follows trial design, not skin pharmacokinetics.
- **Developer-led approach:** topical urolithin A is promoted by its developer Amazentis (Timeline) and by Lancôme as a mitochondrial "skin longevity" active ([NutraIngredients](https://www.nutraingredients.com/Article/2026/02/13/lancome-launches-topical-longevity-skincare-with-timeline/)).
- **Alternative approaches:** topical retinoids, daily sunscreen and vitamin C serums are used for the same goal with independent evidence records; no trial compares them with urolithin A, and each may be used alongside it.
- **Oral route:** Rhonda Patrick discusses 500 to 1,000 mg oral urolithin A daily for mitochondrial goals ([FoundMyFitness](https://www.foundmyfitness.com/episodes/how-urolithin-a-supports-mitochondrial-health)); oral effects on skin are unreported: a combined oral-topical trial posted no results ([NCT06932770](https://clinicaltrials.gov/study/NCT06932770)), and an oral skin trial is recruiting ([NCT07740824](https://clinicaltrials.gov/study/NCT07740824)).
- **Genetic polymorphisms:** no variant is known to alter topical dosing; gut producer status affects only exposure from dietary precursors, not from direct supplements ([Singh et al., 2022](https://pubmed.ncbi.nlm.nih.gov/34117375/)).
- **Sex:** no sex-specific dosing exists; wrinkle data come only from women ([D'Amico et al., 2026](https://pubmed.ncbi.nlm.nih.gov/42866687/)).
- **Age:** trials enrolled middle-aged adults; common practice for older, fragile skin is once-daily use, increasing to twice daily after 2 weeks if tolerated.
- **Baseline biomarkers:** no laboratory marker guides dosing; trials enrolled people with moderate visible wrinkles ([NCT05473832](https://clinicaltrials.gov/study/NCT05473832)), the best-matched starting point.
- **Pre-existing conditions:** for sensitive or barrier-impaired skin (eczema, rosacea), common practice is every other evening for 2 weeks; active disease at the site was an exclusion criterion ([NCT05473832](https://clinicaltrials.gov/study/NCT05473832)).

  
## Discontinuation & Cycling

- **Lifelong or short-term:** positioned as ongoing cosmetic use, but the longest controlled trial with reported results lasted 8 weeks ([D'Amico et al., 2026](https://pubmed.ncbi.nlm.nih.gov/42866687/)); 12-week trials remain unpublished, so long-term benefit and safety are undocumented.
- **Withdrawal effects:** none known; no trial followed participants after stopping.
- **Tapering:** not needed; use can be stopped at once.
- **Persistence after stopping:** unknown whether wrinkle changes persist; the authors list post-treatment follow-up as a gap ([D'Amico et al., 2026](https://pubmed.ncbi.nlm.nih.gov/42866687/)).
- **Cycling:** not studied; no evidence that continuous use loses effect or that cycling preserves it.
- **Temporary pauses:** pausing around aesthetic procedures, skin irritation, pregnancy or breastfeeding carries no known penalty.

  
## Sourcing and Quality

- **Ingredient identity:** trials used Mitopure, synthetic urolithin A of over 99.5% purity, a proprietary, patented ingredient of Amazentis ([D'Amico et al., 2026](https://pubmed.ncbi.nlm.nih.gov/42866687/)).
- **Concentration disclosure:** only a stated 1% concentration matches the effective trial dose; 0.5% was ineffective in trials. Many cosmetic labels list ingredients without percentages, so an undisclosed concentration leaves the dose unknown.
- **Reputable brands:** Lancôme's longevity range, developed with Timeline (the developer's consumer brand), uses Mitopure ([NutraIngredients](https://www.nutraingredients.com/Article/2026/02/13/lancome-launches-topical-longevity-skincare-with-timeline/)); commercial formulas are not necessarily identical to trial creams.
- **Formulation and stability:** urolithin A is highly lipophilic (fat-loving) and poorly water-soluble ([Esposito et al., 2025](https://pubmed.ncbi.nlm.nih.gov/41280710/)), so the cream base matters; opaque, airless packaging limits oxidation of phenolic actives.
- **Third-party testing:** no independent program verifies urolithin A content in cosmetics; testing of oral supplements does not transfer to creams.
- **Vehicle ingredients:** fragrance, essential oils and some preservatives are common irritants; fragrance-free formulas suit sensitive skin.

  
## Practical Considerations

- **Time to effect:** wrinkle depth trended lower at 2 weeks (p = 0.06, not significant) and differed significantly from placebo at 8 weeks ([D'Amico et al., 2026](https://pubmed.ncbi.nlm.nih.gov/42866687/)).
- **Size of effect:** the measured difference is a few percent of wrinkle depth, modest next to marketing language about acting on the skin's biological age ([NutraIngredients](https://www.nutraingredients.com/Article/2026/02/13/lancome-launches-topical-longevity-skincare-with-timeline/)).
- **Common pitfalls:** assuming oral supplements deliver the same skin effect, using products without a stated concentration, expecting results beyond 8-week data, and dropping sunscreen because the active reduced redness in one trial.
- **Regulatory status:** in the U.S. cosmetics need no FDA premarket approval, and claims to regenerate cells make a product a drug ([FDA](https://www.fda.gov/cosmetics/cosmetics-laws-regulations/it-cosmetic-drug-or-both-or-it-soap)); oral urolithin A has a food GRAS notice ([GRN 791](https://www.hfpappexternal.fda.gov/scripts/fdcc/index.cfm?set=GRASNotices&id=791)).
- **Evidence independence:** the manufacturer and its cosmetics partner produced all human skin-aging data, a direct financial interest in adoption ([D'Amico et al., 2026](https://pubmed.ncbi.nlm.nih.gov/42866687/)).
- **Cost and payer context:** products are sold in premium lines and paid out of pocket; insurers do not cover cosmetic skin-aging products, so payer incentives do not shape this evidence, but manufacturer incentives do.

  
## Interaction with Foundational Habits

- **Sleep:** None known (no direction). No study has examined sleep effects; evening application fits a night routine, and the open-label trial used a dedicated night cream ([NCT05473832](https://clinicaltrials.gov/study/NCT05473832)). A topical route makes systemic effects on sleep unlikely.
- **Nutrition:** Indirect. Pomegranate, walnuts and berries supply ellagitannins that about 40% of adults convert to urolithin A ([Singh et al., 2022](https://pubmed.ncbi.nlm.nih.gov/34117375/)); whether dietary urolithin A reaches skin meaningfully is unknown. No nutrient depletion is known; diet does not replace topical dosing.
- **Exercise:** None known. No study links topical urolithin A to exercise; heavy sweating soon after application may dilute or remove the product, so applying after post-workout showering is practical.
- **Stress management:** None known. No effect on cortisol or stress responses has been studied; with minimal expected absorption, hormonal effects are unlikely (theoretical). Stress-related habits such as face touching or harsh scrubbing may add irritation.

  
## Monitoring Protocol & Defining Success

Baseline testing consists of standardized photographs of the crow's-feet area (same lighting, distance, neutral expression and time of day) as the personal reference, plus a 7-day forearm patch test to confirm tolerance. Clinics can add skin-surface profilometry (three-dimensional mapping of skin texture) or hydration readings for objective numbers. Blood tests play no role at baseline, because no systemic effect of topical use has been documented and no laboratory marker predicts response or risk.

Ongoing monitoring follows this cadence: application sites are checked daily for the first 2 weeks, photographs and any clinic measurements are repeated at 2 weeks and 8 weeks, then every 3 months while use continues. Success is a sustained reduction in fine-line depth relative to baseline after 8 weeks without irritation; no change at 8 weeks suggests non-response, given trial timing.

| Biomarker | Optimal Functional Range | Why Measure It? | Context/Notes |
|-----------|--------------------------|-----------------|---------------|
| Wrinkle depth around the eyes (standardized photography or skin-surface profilometry) | No established target; track percentage change from own baseline | Expected to change (efficacy marker) | Trial change: −3.4% with 1% cream versus +4.0% with placebo at 8 weeks ([D'Amico et al., 2026](https://pubmed.ncbi.nlm.nih.gov/42866687/)); profilometry is three-dimensional mapping of the skin surface; lighting, expression and time of day are kept identical |
| Skin hydration (corneometry, an electrical capacitance reading of surface moisture) | No established target; track change from own baseline | Expected to change (efficacy marker) | Reported improved versus untreated skin only in an open-label preprint ([D'Amico et al., 2023](https://www.medrxiv.org/content/10.1101/2023.06.16.23291378v1)); readings are taken at the same time of day after 15 minutes of rest in a temperate room |
| Application-site reaction (forearm repeat open application test) | No established target; track any redness, itching, swelling or blistering | Safety check: a reaction stops use | No reactions occurred in the sponsor's patch test ([NCT05079607](https://clinicaltrials.gov/study/NCT05079607); [D'Amico et al., 2026](https://pubmed.ncbi.nlm.nih.gov/42866687/)); the site is read daily for 7 days before facial use |

Qualitative markers:

- Visibility of fine lines around the eyes in consistent lighting
- Skin smoothness and texture to the touch
- Stinging, burning or redness after application
- Perceived dryness or tightness during the day
- Overall tolerance of the full skincare routine

  
## Emerging Research

- **Unpublished placebo-controlled wrinkle trial:** [NCT06619457](https://clinicaltrials.gov/study/NCT06619457), 36 participants, quadruple-masked (participants, staff, investigators and assessors unaware of assignment) urolithin A cream versus placebo, outcomes wrinkles and skin biological age; completed December 2024, no results posted. A positive result would add a second controlled trial (same sponsor); a null result would weaken the Medium wrinkle grade.
- **Topical plus oral factorial trial (each product tested alone and together):** [NCT06932770](https://clinicaltrials.gov/study/NCT06932770), 72 participants, topical and oral products alone and combined versus placebo, primary outcome wrinkles; completed July 2025, no results posted. A positive result would show whether oral use adds benefit; a null result would argue against combining routes.
- **Open-label trial without placebo:** [NCT07118943](https://clinicaltrials.gov/study/NCT07118943) (four Amazentis topical products, 132 enrolled, primary outcome product acceptance, completed October 2025, no results posted). Lacking placebo, it cannot confirm or refute efficacy; positive or null acceptance data would bear only on tolerability, not on the efficacy grades.
- **Ongoing oral skin trial:** [NCT07740824](https://clinicaltrials.gov/study/NCT07740824), Amazentis, 90 adults, triple-masked (participants, investigators and assessors unaware of assignment), placebo- and active-controlled oral "skin from within" supplement (composition unstated), primary outcome skin aging markers, recruiting, expected completion September 2027. A positive result would offer an oral alternative; a null result would suggest skin benefits are route-specific.
- **Recent safety studies:** [NCT07517874](https://clinicaltrials.gov/study/NCT07517874) (patch test, 112 enrolled, completed June 2026) and [NCT07517900](https://clinicaltrials.gov/study/NCT07517900) (safety in use, 40 enrolled, completed May 2026), no results posted; reactions would strengthen the irritation item, and clean results would support tolerability.
- **Skin penetration:** no study has measured urolithin A in skin after application, which the authors list as a limitation ([D'Amico et al., 2026](https://pubmed.ncbi.nlm.nih.gov/42866687/)); such data could confirm or weaken attribution of effects to urolithin A rather than the cream base.
- **Hair and scalp:** early clinical-case data on hair shedding ([Kwon et al., 2026](https://pubmed.ncbi.nlm.nih.gov/42337978/)) suggest a scalp application that controlled trials could test.
- **Independent replication:** no academic or competitor group has tested topical urolithin A on skin aging; an independent placebo-controlled trial is the single result most likely to raise or lower confidence.

  
## Conclusion

Topical urolithin A is a purified gut-bacteria compound, best known as an oral supplement, now sold in face creams and serums on the idea that helping skin cells renew their energy-producing structures slows visible aging. For health-focused adults willing to invest in a demanding skincare routine, the case rests on a narrow base.

The strongest human finding is a modest reduction in fine-line depth around the eyes after two months of twice-daily use at the higher of two tested strengths, in a single trial of middle-aged women that compared it with an inactive cream. A second company trial found less redness after sunburn-causing light, though it never compared the active cream directly with the inactive one; weaker data suggest better skin moisture. Effects on collagen, inflammation, aging-cell signals and pigment come from laboratory models and gene readings, not from measured skin changes.

Safety looks favorable in the short term: patch tests and trials reported no reactions or only occasional mild irritation, and laboratory concerns about skin barrier signaling, cell growth and blood clotting remain unconfirmed in people. Nothing is known about use beyond two months, absorption into the skin, darker skin types or the skin of people past 75.

The evidence base has a clear conflict of interest: the manufacturer and its cosmetics partner designed, ran and reported every human skin-aging study, and several completed trials remain unpublished. On the current record, topical urolithin A is a plausible but thinly supported addition to other skin-aging approaches.

**[Top](#top) - [Benefits](#expected-benefits) - [Risks](#potential-risks--side-effects) - [Protocol](#therapeutic-protocol)**